Beijing New Leading

Beijing New Leading is a prominent Chinese Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) that provides comprehensive R&D services to the global pharmaceutical industry. Established in 2005, the company offers a full-chain service model covering drug discovery, CMC research, clinical trials (Phase I-IV), and registration services. It has a strong focus on high-end generic drugs and innovative drug development, particularly in therapeutic areas such as oncology, cardiovascular, and the central nervous system. As a subsidiary of Taienkang Pharmaceutical, New Leading operates multiple R&D centers and GMP-compliant manufacturing sites across China. The company is recognized for its expertise in consistency evaluation and bioequivalence studies for the Chinese market. Its integrated platform allows for seamless transition from laboratory-scale development to commercial-scale production.